-- Cyfuse Biomedical K.K (TYO:4892) is advancing its regenerative medicine platform into human trials, with a new therapy aimed at repairing knee bone and cartilage using 3D-printed cell constructs, Nikkei reported Monday.
The physician-led study, conducted with Keio University and Fujita Health University, will test implants created from patients' own fat-derived cells. The trial, expected to begin as early as July, will enroll five patients with idiopathic osteonecrosis of the knee, according to the report.
Cyfuse's technology produces scaffold-free, three-dimensional tissue using living cells, designed to integrate more naturally and lower rejection risk. The knee program marks a step toward addressing conditions where both bone and cartilage are damaged, an area with limited treatment options beyond joint replacement, the report said.
The company has already validated safety in preclinical studies and is positioning the therapy as part of a broader pipeline in regenerative medicine. Earlier this year, Cyfuse began a separate clinical study focused on nerve repair using similar cell-based structures, according to the report.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)